CD86 and B-cell chronic lymphocytic leukemia: In a phase I clinical trial of single-dose CpG 7909 (CpG 2006) in patients with relapsed CLL, patients who received IV CpG 7909 showed enhanced CD20, CD86, and TRAIL expression on CLL B cells, as well as increased NK and T cell counts [22], highlighting the potential of CpG oligodeoxynucleotides to be used as an immune-activating agent in combination therapies.